Gilead Churns Out Additional Trodelvy Data

Gilead Sciences Inc GILD announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) who received two or more prior systemic therapies.
The results were presented at the European Society of Medical Oncology (ESMO21) Congress 2021.
The Company said that a sub-analysis from the study showed significant and clinically meaningful improvements in health-related quality of life over the standard of care (SoC).
Trodelvy received full FDA approval in April to treat metastatic TNBC patients in the second-line or later, in addition to an accelerated OK in urothelial carcinoma the same month.
Related Content: Gilead's Trodelvy Wins FDA Regular Approval For Triple-Negative Breast Cancer.
Among the group of 419 total patients, the 236 who were in the drug arm showed significant and clinically meaningful improvements across the board.
Trodelvy patients saw improvements in global health status, physical functioning, and emotional functioning, compared to those who received SoC of physician's chemotherapy choice.
Gilead also said it observed significant improvements in symptomatic impact of fatigue, pain, difficulty breathing, and insomnia.
Only diarrhea was significantly and meaningfully worse with Trodelvy.
Price Action: GILD stock is down 0.68% at $71.27 during the market session on the last check Thursday.
Check out our coverage of the European Society for Medical Oncology Congress (ESMO21)

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga